179 related articles for article (PubMed ID: 11157031)
1. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides.
de Coninck EC; Kim YH; Varghese A; Hoppe RT
J Clin Oncol; 2001 Feb; 19(3):779-84. PubMed ID: 11157031
[TBL] [Abstract][Full Text] [Related]
2. Mycosis fungoides and the Sézary syndrome.
Kim YH; Hoppe RT
Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
4. Mycosis fungoides.
Zinzani PL; Ferreri AJ; Cerroni L
Crit Rev Oncol Hematol; 2008 Feb; 65(2):172-82. PubMed ID: 17950613
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides.
Kim YH; Chow S; Varghese A; Hoppe RT
Arch Dermatol; 1999 Jan; 135(1):26-32. PubMed ID: 9923777
[TBL] [Abstract][Full Text] [Related]
6. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
[TBL] [Abstract][Full Text] [Related]
7. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.
Quaglino P; Pimpinelli N; Berti E; Calzavara-Pinton P; Alfonso Lombardo G; Rupoli S; Alaibac M; Bottoni U; Carbone A; Fava P; Fimiani M; Mamusa AM; Titli S; Zinzani PL; Bernengo MG;
Cancer; 2012 Dec; 118(23):5830-9. PubMed ID: 22674564
[TBL] [Abstract][Full Text] [Related]
8. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients.
van Doorn R; Van Haselen CW; van Voorst Vader PC; Geerts ML; Heule F; de Rie M; Steijlen PM; Dekker SK; van Vloten WA; Willemze R
Arch Dermatol; 2000 Apr; 136(4):504-10. PubMed ID: 10768649
[TBL] [Abstract][Full Text] [Related]
9. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
Hoppe RT; Wood GS; Abel EA
Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
Kim YH; Bishop K; Varghese A; Hoppe RT
Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract][Full Text] [Related]
12. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
13. Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides.
van Santen S; Roach RE; van Doorn R; Horváth B; Bruijn MS; Sanders CJ; de Pooter JC; van Rossum MM; de Haas ER; Veraart JC; Bekkenk MW; Vermeer MH; Willemze R
JAMA Dermatol; 2016 Sep; 152(9):992-1000. PubMed ID: 27276223
[TBL] [Abstract][Full Text] [Related]
14. A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides.
Li JY; Pulitzer MP; Myskowski PL; Dusza SW; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2013 Sep; 69(3):366-74. PubMed ID: 23685027
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
16. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome.
Suzuki SY; Ito K; Ito M; Kawai K
J Dermatol Sci; 2010 Jan; 57(1):37-43. PubMed ID: 19931424
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides.
Wieser I; Wang C; Alberti-Violetti S; Lyons G; Tran C; Talpur R; Duvic M
Arch Dermatol Res; 2017 Aug; 309(6):453-459. PubMed ID: 28516243
[TBL] [Abstract][Full Text] [Related]
19. Status report of 376 mycosis fungoides patients at 4 years: Mycosis Fungoides Cooperative Group.
Lamberg SI; Green SB; Byar DP; Block JB; Clendenning WE; Epstein EH; Fuks ZY; Golitz LE; Lorincz AL; Michel B; Roenigk HH; Van Scott EJ; Vonderheid EC; Thomas RJ
Cancer Treat Rep; 1979 Apr; 63(4):701-7. PubMed ID: 376140
[TBL] [Abstract][Full Text] [Related]
20. Poikilodermatous mycosis fungoides: a study of its clinicopathological, immunophenotypic, and prognostic features.
Abbott RA; Sahni D; Robson A; Agar N; Whittaker S; Scarisbrick JJ
J Am Acad Dermatol; 2011 Aug; 65(2):313-319. PubMed ID: 21529998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
